Axel Hoos, MD, PhD

Dr. Axel Hoos is Medical Lead in Immunology/Oncology at Bristol-Myers Squibb, holding responsibility for the Ipilimumab (anti CTLA-4) monoclonal antibody program. Dr. Hoos also serves as co-chair of the Executive Committee of the Cancer Vaccine Consortium (CVC) of the New York-based Cancer Research Institute (CRI). In these capacities he is developing promising immunotherapies for life-threatening diseases and is spearheading innovative initiatives to foster the dialogue between regulatory, industry and academic stakeholders, and to improve scientific exchange and the drug development process. Prior to his current role, Dr. Hoos was Senior Director, Clinical Development at Antigenics Inc., a biotechnology company with focus on developing therapies for cancer and infectious diseases, where he was responsible for strategy and execution of clinical trials in all phases of product development. Dr. Hoos studied medicine at Heidelberg University, Heidelberg, Germany and received his PhD in molecular oncology for work in molecular biology and tumor immunology at the German Cancer Research Center in Heidelberg. He trained in surgery with a focus on surgical oncology at the Technical University in Munich and further in surgery, molecular pathology and tumor immunology at Memorial Sloan-Kettering Cancer Center in New York.